Cure Today1d
Radiotherapy and EGFR-TKIs May Improve Treatment Outcomes in Lung Cancer
CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and ...
emjreviews.com6d
New Approach Offers Hope for Drug-Resistant Lung Cancer
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
Scientists use microcellular drones to deliver lung cancer-killing drugs
In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...
BioWorld4d
Hangzhou Highlightll Pharmaceutical identifies tyrosine-protein kinase inhibitors
Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.
Business Wire7d
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...
Mena FN2d
Anticancer Agent TASFYGO Tablets 35Mg (Tasurgratinib Succinate) Launches In Japan For Biliary Tract Cancer With FGFR2 Gene Fusion Or Rearrangements
(Japanese only) (5) Arai Y. et al., Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular ...